公开(公告)号：US20140127304A1

公开(公告)日：2014-05-08

申请号：US14151172

申请日：2014-01-09

Applicant: Norton Healthcare Ltd.

Inventor： Xian-Ming ZENG

IPC: A61K31/439 ,  A61K9/00

CPC classification number: A61K9/19 ,  A61K9/0075 ,  A61K9/1694 ,  A61K31/439 ,  A61K47/26

Abstract: A method of making an inhalable medicament is provided, in particular a new solid-state form of tiotropium bromide. The medicament can be in the form of solid amorphous particles containing an intimate admixture of tiotropium bromide together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least −50.degree. C., such as a sugar and/or sugar alcohol.

Abstract translation: 提供了制备可吸入药物的方法，特别是新型固体形式的噻托溴铵。 药物可以是固体无定形颗粒的形式，其包含噻托溴铵的紧密混合物以及玻璃化转变温度至少为-50度的药学上可接受的共固体。 C.，例如糖和/或糖醇。

公开(公告)号：US20160235678A1

公开(公告)日：2016-08-18

申请号：US15137671

申请日：2016-04-25

Applicant: Norton Healthcare Ltd.

Inventor： Xian-Ming ZENG ,  Sean Kee TEE

IPC: A61K9/16 ,  A61K31/56 ,  A61K31/167 ,  A61K9/00 ,  A61K31/58

CPC classification number: A61K9/1623 ,  A61K9/0075 ,  A61K9/1694 ,  A61K31/137 ,  A61K31/167 ,  A61K31/56 ,  A61K31/58

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

Abstract translation: 本发明提供了一种制备颗粒药物的方法，所述颗粒药物在活性成分和载体的颗粒之间具有较高的均匀性和较低的粘附性。 该方法包括以下步骤：（a）将具有附聚物粒度的一次颗粒附聚物形式的药物活性成分混合，使得附聚物能够通过筛网为50-3000μm的筛网。 和（b）将所得材料混合在混合器中以将附聚物分散成分散在药学上可接受的颗粒载体中的一次颗粒，使得90％或更多的药物活性成分作为具有药学上可接受的颗粒载体的初级颗粒存在， 粒径为50μm以下。

公开(公告)号：US20150150808A1

公开(公告)日：2015-06-04

申请号：US14620929

申请日：2015-02-12

Applicant: Norton Healthcare Ltd.

Inventor： Xian-Ming ZENG

IPC: A61K9/19 ,  A61K9/00 ,  A61K47/26 ,  A61K31/439

CPC classification number: A61K9/19 ,  A61K9/0075 ,  A61K9/1694 ,  A61K31/439 ,  A61K47/26

Abstract: A method of treating at least one of COPD and/or asthma in a subject is provided, wherein an inhalable medicament is administered, in particular a new solid-state form of tiotropium bromide. The medicament can be in the form of solid amorphous particles containing an intimate admixture of tiotropium bromide together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least -50° C., such as a sugar and/or sugar alcohol.

Abstract translation: 提供了治疗受试者中的至少一种COPD和/或哮喘的方法，其中施用可吸入药物，特别是新的固态形式的噻托溴铵。 药物可以是固体无定形颗粒的形式，其包含噻托溴铵与玻璃化转变温度至少为-50℃的药学上可接受的共 - 固体如糖和/或糖醇的混合物。

公开(公告)号：US20170172925A1

公开(公告)日：2017-06-22

申请号：US15453940

申请日：2017-03-09

Applicant: Norton Healthcare Ltd.

Inventor： Xian-Ming ZENG ,  Seah Kee TEE

IPC: A61K9/16 ,  A61K31/56 ,  A61K31/167 ,  A61K9/00 ,  A61K31/58

CPC classification number: A61K9/1623 ,  A61K9/0075 ,  A61K9/1694 ,  A61K31/137 ,  A61K31/167 ,  A61K31/56 ,  A61K31/58

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu·m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu·m or less.